表紙:ヒトマイクロバイオームの世界市場 (~2028年):製品 (プレバイオティクス・プロバイオティクス・食品・診断検査・薬剤)・用途 (治療・診断)・疾患 (感染性・代謝/内分泌)・技術 (ゲノミクス・プロテオミクス・メタボロミクス)・地域別
市場調査レポート
商品コード
996343

ヒトマイクロバイオームの世界市場 (~2028年):製品 (プレバイオティクス・プロバイオティクス・食品・診断検査・薬剤)・用途 (治療・診断)・疾患 (感染性・代謝/内分泌)・技術 (ゲノミクス・プロテオミクス・メタボロミクス)・地域別

Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology(Genomics, Proteomics, Metabolomics)-Global Forecast to 2028

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 172 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.41円
ヒトマイクロバイオームの世界市場 (~2028年):製品 (プレバイオティクス・プロバイオティクス・食品・診断検査・薬剤)・用途 (治療・診断)・疾患 (感染性・代謝/内分泌)・技術 (ゲノミクス・プロテオミクス・メタボロミクス)・地域別
出版日: 2021年03月16日
発行: MarketsandMarkets
ページ情報: 英文 172 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

ヒトマイクロバイオームの市場規模は予測期間中21.3%のCAGRで推移し、2025年の8億9400万米ドルから、2028年には15億9800万米ドルの規模に成長すると予測されています。

ヒトマイクロバイオーム療法の開発への注目の拡大が同市場の成長を推進する見通しです。また、ヒトマイクロバイオームが医薬品開発の有効な標的となることや、疾患の早期発見・診断のためのヒトマイクロバイオームベースの検査法の開発も市場成長を支える要因として期待されています。一方、専門家の不足や十分に研究が進んでいないことなどがさらなる成長を抑制する要因になると予測されています。

製品別では、医薬品の部門が最大のシェアを示しています。臨床試験におけるヒトマイクロバイオームベースの医薬品の数の増加、マイクロバイオームベースの医薬品を開発するための資金の増加などが同部門の成長を推進する見通しです。また、用途別では、診断部門が予測期間中最大のCAGRで成長すると予測されています。

当レポートでは、世界のヒトマイクロバイオームの市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、技術・特許の動向、市場規模の推移・予測、製品・疾患・用途・技術・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 市場成長要因
    • 市場機会
    • 市場課題
    • 市場抑制要因
  • COVID-19の影響
  • 技術分析
  • 規制分析
  • 特許分析

第6章 市場分析・予測:製品別

  • 医薬品
  • 診断検査
  • プロバイオティクス
  • プレバイオティクス
  • その他

第7章 市場分析・予測:疾患別

  • 感染症
  • 胃腸疾患
  • 内分泌・代謝障害
  • その他

第8章 市場分析・予測:用途別

  • 治療
  • 診断

第9章 市場分析・予測:技術別

  • ゲノミクス
    • シーケンシング
    • その他
  • プロテオミクス
  • メタボロミクス

第10章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他
  • その他の地域

第11章 競合情勢

  • 概要
  • 企業の製品のフットプリント
  • 競合シナリオ

第12章 企業プロファイル

  • ENTEROME
  • SERES THERAPEUTICS
  • 4D PHARMA PLC
  • EVELO BIOSCIENCES, INC.
  • OPTIBIOTIX HEALTH PLC
  • SYNLOGIC
  • SECOND GENOME
  • VEDANTA BIOSCIENCES, INC.
  • FERRING PHARMACEUTICALS
  • VITHERA PHARMACEUTICALS, INC.
  • BIOMX
  • DUPOINT
  • KALEIDO
  • YSOPIA BIOSCIENCE
  • FLIGHTPATH
  • FINCH THERAPEUTICS GROUP, INC
  • QUANTBIOME, INC. (DBA THRYVE)
  • VIOME, INC.
  • DAYTWO INC
  • BIOHM
  • ATLAS BIOMED GROUP LIMITED.
  • BIONE
  • LUXIA SCIENTIFIC
  • SUN GENOMICS
  • METABIOMICS

第13章 付録

目次
Product Code: BT 2711

The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.

"By product segment, the drugs segment accounted for the largest share of human microbiome market:"

Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. Drugs segment accounted for the largest product segment in the human microbiome market. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs

"By application, the diagnostics segment is expected to grow at the highest CAGR during the forecast period."

Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR during the forecast period. Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.

"By genomic technologies, the sequencing segment is expected to grow at the highest CAGR during the forecast period."

On the basis of technology, the human microbiome market is further segmented into sequencing and other genomic technologies {PCR, microarray, and fluorescent in situ hybridization (FISH)}. The availability of advanced, efficient, and accurate next-generation sequencing systems at a low cost, along with the reduced cost of sequencing, has greatly boosted the adoption of the latest sequencing technologies in the human microbiome market

"North America: The largest and fastest-growing region in the human microbiome market."

In the human microbiome market, North America is estimated to grow at the highest CAGR during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

  • By Designation: Managers: 55%, Executives: 25%, and CXOs: 20%,
  • By Region: North America: 50%, Europe: 20%, APAC: 20%, and RoW: 10%

Prominent players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics. (US), 4D pharma (UK), Evelo Biosciences (US), OptiBiotix Health (UK), Synlogic (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), BiomX (Israel), DuPont (US), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US).

Research Coverage:

The report segments the human microbiome market based on region (Asia Pacific, Europe, North America, and RoW), product (prebiotics, probiotics, drugs, diagnostic tests, and other products), technology (Genomics, Proteomics, and Metabolomics), application (therapeutics and diagnostics), disease (hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies, and other end users). The report also provides a comprehensive review of market drivers, opportunities, restraints, and challenges in the human microbiome market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED FOR THE HUMAN MICROBIOME MARKET
    • 1.3.2 MARKETS COVERED FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET
    • 1.3.3 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME RESEARCH SPENDING MARKET)
    • 1.3.4 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME DIAGNOSTIC APPLICATIONS MARKETS)
    • 1.3.5 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME THERAPEUTIC APPLICATION MARKETS)
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY SOURCES
    • FIGURE 1 BREAKDOWN OF PRIMARIES: HUMAN MICROBIOME MARKET
  • 2.2 MARKET DATA ESTIMATION AND TRIANGULATION
    • FIGURE 2 DATA TRIANGULATION METHODOLOGY
    • 2.2.1 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 MARKET SIZE ESTIMATION APPROACH: R&D SPENDING ANALYSIS-BASED ESTIMATION (FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET)
    • FIGURE 4 HUMAN MICROBIOME RESEARCH SPENDING MARKET SIZE (USD MILLION): FINAL MARKET SIZE
    • 2.2.2 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 5 FINAL CAGR PROJECTIONS (2020-2025)
    • 2.2.3 POTENTIAL MARKET SIZE CALCULATION FOR HUMAN MICROBIOME MARKET
    • FIGURE 6 HUMAN MICROBIOME MARKET SIZE BASED ON EPIDEMIOLOGY APPROACH
    • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.3 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2025 VS. 2028 (USD MILLION)
    • FIGURE 9 HUMAN MICROBIOME MARKET SHARE, BY APPLICATION, 2024
    • FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2025 VS. 2028 (USD MILLION)
    • FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE HUMAN MICROBIOME MARKET

4 PREMIUM INSIGHTS

  • 4.1 HUMAN MICROBIOME: MARKET OVERVIEW
    • FIGURE 12 INCREASING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE THE GROWTH OF THIS MARKET
  • 4.2 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY (2020 VS. 2025)
    • FIGURE 13 GENOMIC TECHNOLOGIES DOMINATED THE HUMAN MICROBIOME RESEARCH SPENDING MARKET IN 2020
  • 4.3 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2024)
  • 4.4 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY (2020-2025)
    • FIGURE 14 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Increasing focus on human microbiome therapeutics development
      • 5.2.1.2 Human microbiome as a validated target for drug development
      • 5.2.1.3 Development of human microbiome-based tests for early disease detection & diagnosis
    • 5.2.2 MARKET OPPORTUNITIES
      • 5.2.2.1 Increasing collaborations between public-private organizations
    • 5.2.3 MARKET CHALLENGES
      • 5.2.3.1 Government regulations
      • 5.2.3.2 Lack of expertise and inadequate research
    • 5.2.4 MARKET RESTRAINTS
      • 5.2.4.1 Barriers in proving the causal link between dysbiosis and diseases
  • 5.3 IMPACT OF THE COVID-19 ON THE MARKET
  • 5.4 TECHNOLOGY ANALYSIS
  • 5.5 REGULATORY ANALYSIS
    • 5.5.1 FOR HUMAN MICROBIOME-BASED DRUGS CATEGORY
    • 5.5.2 FOR HUMAN MICROBIOME-BASED FOODS CATEGORY
  • 5.6 PATENT ANALYSIS

6 HUMAN MICROBIOME MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 1 HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • 6.2 DRUGS
    • 6.2.1 INCREASING NUMBER OF MICROBIOME-BASED DRUGS IN THE PIPELINE IS A KEY FACTOR DRIVING MARKET GROWTH
    • TABLE 2 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2022-2028 (USD MILLION)
    • TABLE 3 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY 2022-2028 (USD MILLION)
  • 6.3 DIAGNOSTIC TESTS
    • 6.3.1 GROWING CONSUMER AWARENESS ABOUT MICROBIOME-BASED TESTS TO DRIVE MARKET GROWTH
    • TABLE 4 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2019-2028 (USD MILLION)
    • TABLE 5 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY 2019-2028 (USD MILLION)
  • 6.4 PROBIOTICS
    • 6.4.1 ONGOING RESEARCH ON PROBIOTICS IS PROMOTING ITS CREDIBILITY IN HEALTH CLAIMS AND SAFETY, THUS DRIVING MARKET GROWTH
    • TABLE 6 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023-2028 (USD MILLION)
    • TABLE 7 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2019-2028 (USD MILLION)
  • 6.5 PREBIOTICS
    • 6.5.1 DEVELOPMENT OF TARGETED PREBIOTICS IN ENHANCING GUT MICROBIOTA IS THE KEY GROWTH DRIVER FOR THIS SEGMENT
    • TABLE 8 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023-2028 (USD MILLION)
    • TABLE 9 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023- 2028 (USD MILLION)
  • 6.6 OTHER PRODUCTS
    • TABLE 10 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023-2028 (USD MILLION)
    • TABLE 11 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2028 (USD MILLION)

7 HUMAN MICROBIOME MARKET, BY DISEASE

  • 7.1 INTRODUCTION
    • TABLE 12 HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
  • 7.2 INFECTIOUS DISEASES
    • 7.2.1 INCREASING NUMBER OF CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO DRIVE MARKET GROWTH
    • TABLE 13 DEVELOPMENT OF MICROBIOME-BASED DRUGS FOR INFECTIOUS DISEASES
    • TABLE 14 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2027 (USD MILLION)
    • TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2028 (USD MILLION)
  • 7.3 GASTROINTESTINAL DISEASES
    • 7.3.1 INCREASING NUMBER OF CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO DRIVE MARKET GROWTH
    • TABLE 16 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022-2028 (USD MILLION)
    • TABLE 17 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022-2028 (USD MILLION)
  • 7.4 ENDOCRINE & METABOLIC DISORDERS
    • 7.4.1 THE DEVELOPMENT OF MICROBIOME MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS DRIVES MARKET GROWTH
    • TABLE 18 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2022-2028 (USD MILLION)
    • TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2022-2028 (USD MILLION)
  • 7.5 CANCER
    • 7.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN THE TREATMENT OF PELVIC AND COLON CANCER
    • TABLE 20 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2022-2028 (USD MILLION)
    • TABLE 21 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2022-2028 (USD MILLION)
  • 7.6 OTHER DISEASES
    • TABLE 22 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2022-2028 (USD MILLION)
    • TABLE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2028 (USD MILLION)

8 HUMAN MICROBIOME MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 24 HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
  • 8.2 THERAPEUTIC APPLICATIONS
    • 8.2.1 AVAILABILITY OF FUNDING FOR THE DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET GROWTH
    • TABLE 25 HUMAN MICROBIOME MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2019-2028 (USD MILLION)
    • TABLE 26 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2019-2028 (USD MILLION)
  • 8.3 DIAGNOSTIC APPLICATIONS
    • 8.3.1 INCREASING FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET GROWTH
    • TABLE 27 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2019-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019-2028 (USD MILLION)

9 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY

  • 9.1 INTRODUCTION
    • TABLE 29 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
  • 9.2 GENOMICS
    • TABLE 30 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 31 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 32 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 33 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
    • 9.2.1 SEQUENCING
    • TABLE 35 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 36 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 37 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 38 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 39 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY METHOD, 2018-2025 (USD MILLION)
      • 9.2.1.1 16S rRNA Sequencing Method
        • 9.2.1.1.1 This method is a cost-effective technique for the identification of bacterial strains
    • TABLE 40 16S RRNA SEQUENCING METHOD, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 41 NORTH AMERICA: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 42 EUROPE: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018-2025 (USD MILLION)
      • 9.2.1.2 Whole-Genome Sequencing(WGS)Method
        • 9.2.1.2.1 WGS helps generate accurate reference genomes for microbial identification
    • TABLE 44 WGS METHOD, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 45 NORTH AMERICA: WGS METHOD, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 46 EUROPE: WGS METHOD, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: WGS METHOD, BY COUNTRY, 2018-2025 (USD MILLION)
      • 9.2.1.3 Other Sequencing Methods
    • TABLE 48 OTHER SEQUENCING METHODS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 49 NORTH AMERICA: OTHER SEQUENCING METHODS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 50 EUROPE: OTHER SEQUENCING METHODS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: OTHER SEQUENCING METHODS BY COUNTRY, 2018-2025 (USD MILLION)
    • 9.2.2 OTHER GENOMIC TECHNOLOGIES
    • TABLE 52 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 53 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 54 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 9.3 PROTEOMICS
    • 9.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMIC TECHNOLOGIES TO DRIVE MARKET GROWTH
    • TABLE 56 PROTEOMICS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 57 NORTH AMERICA: PROTEOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 58 EUROPE: PROTEOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: PROTEOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
  • 9.4 METABOLOMICS
    • 9.4.1 ADVANTAGES OF METABOLOMICS OVER GENOMICS AND PROTEOMICS IN MICROBIOME RESEARCH TO DRIVE MARKET GROWTH
    • TABLE 60 METABOLOMICS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 61 NORTH AMERICA: METABOLOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 62 EUROPE: METABOLOMICS, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: METABOLOMICS, BY COUNTRY, 2018-2025 (USD MILLION)

10 HUMAN MICROBIOME MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 64 HUMAN MICROBIOME MARKET, BY REGION, 2019-2028 (USD MILLION)
    • TABLE 65 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 66 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
    • TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
    • TABLE 69 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2019-2025 (USD MILLION)
    • TABLE 70 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 71 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 72 NORTH AMERICA: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 73 NORTH AMERICA: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Increasing investments by NIH in support of microbiome research is driving the market growth in the US
    • TABLE 74 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
    • TABLE 75 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
    • TABLE 76 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
    • TABLE 77 US: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 78 US: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 79 US: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing government support and funds support market growth for microbiome research in Canada
    • TABLE 80 INDICATIVE LIST OF PROJECTS ON THE HUMAN MICROBIOME IN 2018
    • TABLE 81 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
    • TABLE 82 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
    • TABLE 83 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
    • TABLE 84 CANADA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 85 CANADA: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 86 CANADA: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 87 EU MICROBIOME PROJECT
    • TABLE 88 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
    • TABLE 89 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
    • TABLE 90 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
    • TABLE 91 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 92 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 93 EUROPE: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 94 EUROPE: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Extended applications of microbiome research to therapeutic areas to boost the adoption of microbiome-based products in Germany
    • TABLE 95 GERMANY: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 96 GERMANY: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 97 GERMANY: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Increasing focus on the development of microbiome-based products in the UK to drive market growth
    • TABLE 98 UK: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 99 UK: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 100 UK: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing funding to boost the development of microbiome-based products in Europe
    • TABLE 101 FRANCE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 102 FRANCE: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 103 FRANCE: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.3.4 ROE
    • TABLE 104 ROE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 105 ROE: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 106 ROE: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 107 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
    • TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
    • TABLE 109 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 113 ASIA PACIFIC: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 A large number of human microbiome research studies are conducted in China, thus driving market growth
    • TABLE 114 INDICATIVE LIST OF HUMAN MICROBIOME RESEARCH STUDIES CONDUCTED IN CHINA
    • TABLE 115 CHINA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 116 CHINA: GENOMICS TECHNOLOGY MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 117 CHINA: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Increasing focus on funding for microbiome-based products to drive market growth
    • TABLE 118 JAPAN: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 119 JAPAN: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 120 JAPAN: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Government funding to drive the development of microbiome-based products in India
    • TABLE 121 INDIA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 122 INDIA: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 123 INDIA: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
    • 10.4.4 ROAPAC
    • TABLE 124 ROAPAC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 125 ROAPAC: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 126 ROAPAC: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)
  • 10.5 REST OF THE WORLD (ROW)
    • TABLE 127 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
    • TABLE 128 ROW: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
    • TABLE 129 ROW: HUMAN MICROBIOME MARKET, BY DISEASE, 2022-2028 (USD MILLION)
    • TABLE 130 ROW: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 131 ROW: GENOMICS MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 132 ROW: SEQUENCING MARKET, BY METHOD, 2018-2025 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 COMPANY PRODUCT FOOTPRINT
    • FIGURE 18 PRODUCT PORTFOLIO ANALYSIS: HUMAN MICROBIOME MARKET
  • 11.3 COMPETITIVE SCENARIO
    • TABLE 133 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2020-JANUARY 2021

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View)**
  • 12.1 ENTEROME
  • 12.2 SERES THERAPEUTICS
    • FIGURE 19 SERES THERAPEUTICS: COMPANY SNAPSHOT (2019)
  • 12.3 4D PHARMA PLC
    • FIGURE 20 4D PHARMA PLC: COMPANY SNAPSHOT (2019)
  • 12.4 EVELO BIOSCIENCES, INC.
    • FIGURE 21 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2019)
  • 12.5 OPTIBIOTIX HEALTH PLC
    • FIGURE 22 OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2019)
  • 12.6 SYNLOGIC
    • FIGURE 23 SYNLOGIC: COMPANY SNAPSHOT (2019)
  • 12.7 SECOND GENOME
  • 12.8 VEDANTA BIOSCIENCES, INC.
  • 12.9 FERRING PHARMACEUTICALS
  • 12.10 VITHERA PHARMACEUTICALS, INC.
  • 12.11 BIOMX
    • FIGURE 24 BIOMX: COMPANY SNAPSHOT (2019)
  • 12.12 DUPOINT
    • FIGURE 25 DU PONT: COMPANY SNAPSHOT (2019)
  • 12.13 KALEIDO
    • FIGURE 26 KALEIDO: COMPANY SNAPSHOT (2019)
  • 12.14 YSOPIA BIOSCIENCE
  • 12.15 FLIGHTPATH
  • 12.16 FINCH THERAPEUTICS GROUP, INC
  • 12.17 QUANTBIOME, INC. (DBA THRYVE)
  • 12.18 VIOME, INC.
  • 12.19 DAYTWO INC
  • 12.20 BIOHM
  • 12.21 ATLAS BIOMED GROUP LIMITED.
  • 12.22 BIONE
  • 12.23 LUXIA SCIENTIFIC
  • 12.24 SUN GENOMICS
  • 12.25 METABIOMICS
  • *Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS 176